BACKGROUND/AIM: In the diagnosis of malignant mesothelioma (MM) there still is a lack of specific and sensitive screening biomarkers: this study examined the discriminatory power of a panel of serum/plasma biomarkers. PATIENTS AND METHODS: The study involved four groups: (a) individuals previously exposed to asbestos with asbestosis; (b) patients with MM; (c) patients with non-small cell lung cancer; and (d) controls without any evidence of malignancy. The concentrations of mesothelin, chitinase-3-like-1 (YKL-40), vascular endothelial growth factor (VEGF), endothelin-1, interleukin-8 (IL-8) and fibulin-3 in the serum of patients were determined. RESULTS: Patients with MM had significantly higher serum levels of mesothelin (p<0.001), YKL-40 (p<0.001), IL-8 (p<0.001) and VEGF (p<0.01) than controls. The cut-off point for MM was 1.26 nM for mesothelin alone, and 167 pg/ml for YKL-40 alone; the presence of both markers above these cut-off levels improved diagnostic specificity. CONCLUSION: The addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with MM.
BACKGROUND/AIM: In the diagnosis of malignant mesothelioma (MM) there still is a lack of specific and sensitive screening biomarkers: this study examined the discriminatory power of a panel of serum/plasma biomarkers. PATIENTS AND METHODS: The study involved four groups: (a) individuals previously exposed to asbestos with asbestosis; (b) patients with MM; (c) patients with non-small cell lung cancer; and (d) controls without any evidence of malignancy. The concentrations of mesothelin, chitinase-3-like-1 (YKL-40), vascular endothelial growth factor (VEGF), endothelin-1, interleukin-8 (IL-8) and fibulin-3 in the serum of patients were determined. RESULTS:Patients with MM had significantly higher serum levels of mesothelin (p<0.001), YKL-40 (p<0.001), IL-8 (p<0.001) and VEGF (p<0.01) than controls. The cut-off point for MM was 1.26 nM for mesothelin alone, and 167 pg/ml for YKL-40 alone; the presence of both markers above these cut-off levels improved diagnostic specificity. CONCLUSION: The addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with MM.
Authors: Clementina Mesaros; Andrew J Worth; Nathaniel W Snyder; Melpo Christofidou-Solomidou; Anil Vachani; Steven M Albelda; Ian A Blair Journal: Bioanalysis Date: 2015 Impact factor: 2.681
Authors: Daniel G Weber; Swaantje Casjens; Georg Johnen; Oleksandr Bryk; Irina Raiko; Beate Pesch; Jens Kollmeier; Torsten T Bauer; Thomas Brüning Journal: PLoS One Date: 2014-12-03 Impact factor: 3.240
Authors: Selina Tsim; Caroline Kelly; Laura Alexander; Carol McCormick; Fiona Thomson; Rosie Woodward; John E Foster; David B Stobo; Jim Paul; Nick A Maskell; Anthony Chalmers; Kevin G Blyth Journal: BMJ Open Date: 2016-11-24 Impact factor: 2.692
Authors: Michaela B Kirschner; Emily Pulford; Mir Alireza Hoda; Anita Rozsas; Kim Griggs; Yuen Yee Cheng; J James B Edelman; Steven C Kao; Rebecca Hyland; Yawen Dong; Viktoria László; Thomas Klikovits; Michael P Vallely; Michael Grusch; Balazs Hegedus; Balazs Dome; Walter Klepetko; Nico van Zandwijk; Sonja Klebe; Glen Reid Journal: Br J Cancer Date: 2015-08-11 Impact factor: 7.640
Authors: Michele Carbone; Shreya Kanodia; Ann Chao; Aubrey Miller; Anil Wali; David Weissman; Alex Adjei; Francine Baumann; Paolo Boffetta; Brenda Buck; Marc de Perrot; A Umran Dogan; Steve Gavett; Alessandro Gualtieri; Raffit Hassan; Mary Hesdorffer; Fred R Hirsch; David Larson; Weimin Mao; Scott Masten; Harvey I Pass; Julian Peto; Enrico Pira; Ian Steele; Anne Tsao; Gavitt Alida Woodard; Haining Yang; Shakun Malik Journal: J Thorac Oncol Date: 2016-08 Impact factor: 15.609